Extended Data Fig. 5: Exploratory analyses of immune mechanisms underlying sotorasib response and resistance.

(a) Prevalence of KC, KL, and KP tumor types (left panel) or TP53, STK11, and KEAP1 mutation status (right panels) based on PD-L1 expression among patients treated with sotorasib in the combined dataset. (b) Kaplan-Meier curve of PFS based on PD-L1 TPS for patients treated with sotorasib in the combined dataset. (c) Prevalence of immune subtypes based on PD-L1 TPS for patients with RNA-seq and PD-L1 expression data among patients treated with sotorasib from the combined dataset. (d) Kaplan-Meier curve of PFS based on immune subtypes for patients treated with sotorasib in CB100 (left panel) and CB200 (right panel). (e) Prevalence of patients with fast progression or long-term benefit across immune subtypes for patients treated with sotorasib from the combined dataset. (f) Kaplan-Meier curve of PFS for patients with inflammatory subtype treated with sotorasib in the combined dataset. CB100, CodeBreaK 100; CB200, CodeBreaK 200; IFN-ɣ, interferon gamma; KRAS, Kirsten rat sarcoma virus; MUT, mutant; PD-L1, programmed death-ligand 1; PFS, progression-free survival; TGF-β, transforming growth factor beta; RNA-seq, RNA-sequencing; TP53, tumor protein p53; TPS, tumor proportion score; WT, wild-type.